HCPCS code Q5123: Billing guide for rituximab-arrx (Riabni)

Key Takeaways

HCPCS code Q5123 describes injection, rituximab-arrx, biosimilar, (Riabni), 10 mg – effective July 1, 2021, and valid for 2026 billing

Each billing unit equals 10 mg; a 500 mg infusion dose requires 50 units – under-reporting units is one of the most common claim errors

Q5123 is subject to mandatory CMS JW/JZ modifier policy for drug waste reporting on multi-dose vials

Pabau’s claims management software helps infusion centers track Q5123 unit calculations, modifier flags, and prior authorization status in one place

HCPCS code Q5123: Definition and clinical description

HCPCS code Q5123 is the Level II code for injection, rituximab-arrx, biosimilar, (Riabni), 10 mg. It bills by the 10 mg unit, and infusion doses commonly run to 500 mg or 1,000 mg per session.

The Centers for Medicare and Medicaid Services (CMS) established the code effective July 1, 2021, following FDA approval of Riabni as a biosimilar to reference rituximab (Rituxan). It’s valid for 2026 billing under the CMS category Cancer, Vision and Other Associated Drugs.

Q5123 code properties at a glance

Before billing, confirm these verified code attributes against the current-year CMS HCPCS file. Coverage code C (Carrier judgment) means local Medicare Administrative Contractors (MACs) determine coverage based on individual clinical circumstances rather than a national coverage determination.

Indications and clinical context for HCPCS code Q5123

Riabni (rituximab-arrx) is a CD20-directed monoclonal antibody. It binds to the CD20 antigen expressed on the surface of B-lymphocytes and triggers cell death. The same mechanism that makes reference rituximab effective in treating B-cell malignancies and autoimmune conditions applies to Riabni as a biosimilar.

FDA-approved indications that support medical necessity for Q5123 billing include the following conditions. Coders should select the most specific ICD-10-CM code available and document which indication drove the treatment decision.

• Non-Hodgkin lymphoma (NHL) – including diffuse large B-cell lymphoma and follicular lymphoma
• Chronic lymphocytic leukemia (CLL) – in combination with chemotherapy regimens
• Rheumatoid arthritis (RA) – for adult patients with moderate-to-severe disease inadequately controlled by one or more TNF inhibitors
• Granulomatosis with polyangiitis (GPA) – formerly Wegener’s granulomatosis
• Microscopic polyangiitis (MPA) – including induction and maintenance therapy
• Pemphigus vulgaris – a serious autoimmune blistering disorder

Off-label use exists for several conditions, but claims billed against non-approved indications face higher scrutiny and prior authorization denial rates. Local Coverage Determinations (LCDs) from individual MACs govern which diagnoses qualify under their respective jurisdictions. CMS maintains the annual list of CPT/HCPCS codes covered under Medicare Part B.

Maintaining thorough clinical documentation forms for each infusion encounter is essential. The physician’s order must include the indication, dose, route, and frequency. Without this, even a correctly coded claim can be denied on audit.

Dosing units and calculation for Q5123 billing

Q5123 bills per 10 mg of rituximab-arrx administered. Rituximab dosing is weight-based for some indications and fixed-dose for others, so the number of units billed changes with each patient and each cycle. Getting this right is where many infusion billing teams lose money or face compliance exposure.

Round up to the nearest whole unit when the calculated dose does not divide evenly by 10 mg, per CMS billing rules (Medicare Claims Processing Manual, Pub. 100-04, Ch. 17). For example, a 10 mg descriptor with 47 mg administered bills as 5 units, not 4.

Bill only for the dose documented as administered, never for the full vial content unless every milligram was used.

Accurate unit tracking is one of the areas where claims management workflows within practice management software provide the most direct financial return. When unit counts are calculated manually and transcribed into the claim, transcription errors are common and often go undetected until a payer audit.

Medicare reimbursement and ASP methodology for Q5123

Medicare Part B reimburses Q5123 under the Average Sales Price (ASP) methodology at ASP + 6%. CMS updates ASP-based reimbursement rates quarterly, so the rate applicable in Q1 2026 differs from Q2 2026. Always verify the current payment amount using the CMS Physician Fee Schedule lookup tool before submitting claims, rather than relying on rates from a prior quarter.

The ASP + 6% rate applies to the units administered and billed. Coverage code C means individual MACs exercise judgment on whether a given clinical scenario qualifies.

Rheumatology and oncology practices billing Q5123 under a buy-and-bill model typically receive the Part B drug payment directly. Practices using specialty pharmacy arrangements may have different reimbursement flows depending on the payer contract.

For infusion therapy EMR software integrations, confirming that drug payment amounts are pulled quarterly is a key audit readiness step. Stale reimbursement data in your billing system causes underpayment reconciliation problems that compound over time.

Simplify infusion billing with Pabau

Track Q5123 unit calculations, modifier flags, and prior authorization status without spreadsheets. See how Pabau keeps your infusion billing clean and audit-ready.

Book a demo

Modifiers for HCPCS code Q5123

Two modifier categories apply to Q5123 claims: the mandatory CMS drug waste modifiers and situational modifiers that reflect specific billing circumstances. Submitting without the required waste modifier is a compliance risk and triggers claim-level edits at many MACs.

JW and JZ modifiers (mandatory CMS policy)

CMS requires the JW or JZ modifier on all single-dose vial (SDV) and multi-dose vial (MDV) drug claims under Medicare Part B. Q5123 is listed in the CMS JW/JZ Modifier Policy HCPCS Codes document, making compliance mandatory, not optional.

• JW modifier – append to a separate line item for drug units discarded (waste). The JW line bills the discarded amount and receives $0 reimbursement. It creates the documented trail that the waste occurred and was not billed for payment.
• JZ modifier – append when no drug was wasted (the entire amount drawn was administered). Signals to the payer that there was zero discarded drug for this encounter.

Example: A patient receives a 500 mg dose. Riabni is supplied in 500 mg/50 mL (10 mg/mL) vials. If the provider opens one vial and uses all 500 mg, bill 50 units of Q5123 with modifier JZ.

If the dose leaves 50 mg unused, bill 45 units of Q5123 without a modifier on the paid line, then bill 5 units of Q5123 with modifier JW on a separate line at $0.

Other situational modifiers

• SB – nurse midwife services (rarely applicable to infusion but available)
• GY – item or service statutorily excluded from Medicare coverage; used when billing for a non-covered indication to generate an Advance Beneficiary Notice (ABN) denial
• GA – waiver of liability on file when a non-covered service is provided and an ABN has been obtained from the patient

For practices managing infusion clinic best practices, building a modifier decision tree into your pre-billing workflow prevents the most common Q5123 claim edits.

Related HCPCS codes: Rituximab biosimilars and reference biologic

Q5123 is one of four HCPCS codes covering rituximab and its biosimilars. Each code maps to a distinct biosimilar product, and billing the wrong code for the product administered is a misrepresentation risk.

Verify the NDC on the drug label against the correct HCPCS code before claim submission. CMS’s published NDC-HCPCS crosswalk files and the AAPC Codify HCPCS lookup both provide current NDC crosswalk data for biosimilar Q-codes.

Q5123 covers only the drug itself, so bill the infusion administration separately. Oncology indications typically pair it with CPT 96413 (chemotherapy IV infusion, initial hour), while autoimmune indications like rheumatoid arthritis typically pair it with CPT 96365 (non-chemotherapy IV infusion, initial hour).

Other infused biologics that follow a similar drug-plus-administration billing pattern include HCPCS J2323 (natalizumab) and HCPCS S9379 for home infusion therapy arrangements.

Use J3590 (unclassified biologic) only when a rituximab biosimilar product does not yet have an assigned Q-code. As of 2026, all four products above have specific codes; J3590 submission for any of them is incorrect and increases denial probability.

Louisiana Medicaid applies specific dosing frequency limits across all four codes. Per Louisiana Department of Health policy, Q5123 (along with J9312, Q5115, and Q5119) is limited to no more than 100 units every two weeks for the initial dose when billed with a diagnosis of rheumatoid arthritis or pemphigus vulgaris.

Practices billing Louisiana Medicaid for patient compliance documentation under those indications must track cumulative units against this frequency threshold.

Documentation requirements and prior authorization

Q5123 claims require documentation that establishes medical necessity for each infusion encounter. Carrier judgment coverage means the MAC evaluates records when a claim is selected for review, so complete records from day one are essential.

Required documentation elements

• Confirmed diagnosis with the supporting ICD-10-CM code (see FAQ section for common codes)
• Physician order specifying drug name (rituximab-arrx / Riabni), dose in mg, route of administration (IV infusion), and frequency
• Chemotherapy or drug administration note with start and stop times for the infusion
• Drug administration record showing the lot number, NDC, dose drawn, dose administered, and any waste documented per JW/JZ policy
• For RA and autoimmune indications: documentation of inadequate response to prior therapy (TNF inhibitor failure for RA)
• Prior authorization approval number, if required by the payer

Prior authorization considerations

Prior authorization requirements for Q5123 vary by payer, indication, and whether buy-and-bill or specialty pharmacy is used. Medicare Fee-for-Service does not require prior authorization for Part B drugs, but Medicare Advantage plans frequently do. UnitedHealthcare’s commercial medical drug policy for rituximab products (including Q5123) requires authorization for most indications and specifies step therapy requirements.

Using digital intake and consent forms to capture the patient’s prior treatment history at the point of intake reduces the back-and-forth when submitting prior authorization requests. Payers typically require this information as part of the clinical criteria review.

For EHR integration for infusion centers, connecting your practice management system to your pharmacy benefits manager portal helps flag which patients require authorization before the infusion date, not after.

HCPCS code Q5123 and billing compliance

Rituximab biosimilar claims sit in a higher-scrutiny segment of Medicare Part B drug billing. The ASP-based methodology, mandatory waste reporting, and indication-specific coverage rules create multiple compliance checkpoints that billing teams must navigate on every claim.

Key compliance risks for Q5123 billing include: billing J9312 when Riabni was administered (product mismatch), billing more units than the dose administered supports (overbilling), failing to append JW/JZ modifiers (mandatory policy violation), and submitting without a matching NDC on the claim when required by the payer.

Practices operating under HIPAA-compliant medical billing standards should treat Q5123 as a code that warrants periodic internal audit. Pull a sample of claims every quarter, verify unit counts against the administration records, confirm modifier usage, and reconcile reimbursement received against ASP rates for that quarter.

Building compliance management checkpoints into your billing workflow, rather than relying on retrospective audits, is the most effective way to prevent the pattern of errors that triggers payer audits.

Conclusion

HCPCS code Q5123 is a high-value, high-scrutiny code. Getting the unit calculation right, applying JW or JZ modifiers correctly, matching the NDC to the specific biosimilar administered, and maintaining indication-specific documentation are the four pillars of clean Q5123 claim submission. Errors in any one of these areas trigger denials, demand letters, and audit exposure.

Pabau’s integrated practice management software gives infusion and oncology billing teams the workflow infrastructure to track drug administration, automate modifier prompts, and maintain documentation that satisfies MAC review. To see how Pabau can tighten your Q5123 billing workflow, book a demo with the team.

Continue your research

Need to manage infusion billing across multiple locations? IV therapy EMR software covers how practice management tools support multi-site infusion billing and documentation workflows.

Looking for coding guidance on other drug administration codes? Pabau’s procedure codes resource hub covers billing and coding guides across specialties and drug categories.

Frequently asked questions